Verve Therapeutics : Initial Data from the Heart 2 Clinical Trial of VERVE 102.

Published: 2025-04-14 10:14:05 ET VERV

Today's agenda

Opening remarks and overview of PCSK9 program

Initial results from Heart-2 clinical trial of VERVE-102

VERVE-102 next steps and closing remarks

Q&A

Sekar Kathiresan, M.D.

Co-Founder and Chief

Executive Officer

Scott Vafai, M.D.

Senior Vice President,

Clinical Development

Sekar Kathiresan, M.D.

Co-Founder and Chief

Executive Officer

Sekar Kathiresan, M.D., Co-Founder and Chief Executive Officer Allison Dorval, Chief Financial Officer

Scott Vafai, M.D., Senior Vice President, Clinical Development

Forward looking statements and disclaimers

This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the Company's ongoing Heart-2 clinical trial; the timing and availability of data for the Heart-2 trial and timing for initiation of a Phase 2 clinical trial for VERVE-102; the timing for delivery of the opt-in package and of Eli Lilly and Company's decision for the PCSK9 program; the Company's strategic plans and prospects; the potential advantages and therapeutic potential of VERVE-102; market opportunity estimates or projections; and the period over which the Company believes that its existing cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses. All statements, other than statements of historical facts, contained in this presentation, including statements regarding the Company's strategy, future operations, future financial position, prospects, plans and objectives of management, are forward- looking statements. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements

contain these identifying words. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward- looking statements. These risks and uncertainties include, but are not limited to, risks associated with the Company's limited operating history; the Company's ability to timely submit and receive approvals of regulatory applications for its product candidates; advance its product candidates in preclinical studies and clinical trials; initiate, enroll and complete its ongoing and future clinical trials on the timeline expected or at all; correctly estimate the potential patient population and/or market for the Company's product candidates; replicate in clinical trials positive results found in preclinical studies and/or earlier-stage clinical trials of VERVE-101, VERVE-102 and VERVE-201; advance the development of its product candidates under the timelines it anticipates in preclinical studies and in current and future clinical trials; obtain, maintain or protect intellectual property rights related to its

product candidates; manage expenses; and raise the substantial additional capital needed to achieve its business objectives. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward- looking statements, see the "Risk Factors" section, as well as discussions of potential risks, uncertainties and other important factors, in the Company's most recent filings with the Securities and Exchange Commission and in other filings that the Company makes with the Securities and Exchange Commission in the future. In addition, the forward-looking statements included in this presentation represent the Company's views as of the date hereof and should not be relied upon as representing the Company's views as of any date subsequent to the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.

ASCVD and HeFH:

with current treatment options, majority of patients are not at LDL-C goal

Atherosclerotic Cardiovascular Disease (ASCVD)Heterozygous Familial Hypercholesterolemia (HeFH)

What is ASCVD?

What is HeFH?

Build-up of cholesterol-driven deposits in artery walls

Inherited disease characterized by high levels

that restricts healthy blood flow and can cause heart

of LDL-C [LDL-C ≥ 190 mg/dL] that frequently results

disease, stroke, and peripheral vascular disease

in early-onset ASCVD

>30M

~75%

>3M

97%

Patients with ASCVD not at

ASCVD patients are

Patients with HeFH in

HeFH patients are not

LDL-C goal in U.S. + EU1,2

not at LDL-C goal2

U.S. + EU3

at LDL-C goal4

ASCVD is the leading cause

HeFH is the most prevalent

of death in the world

genetic disease in humans

1. Ray KK et al. European Journal of Preventive Cardiology 2021. 2. Gu J et al. Am J Prev Cardiol 2022. 3. de Ferranti et al. Circulation 2016. 4. Vallejo-Vaz et al. Lancet 2021

LDL-C, low-density lipoprotein cholesterol

Treatment and prevention of ASCVD:

keep blood cholesterol as low as possible for as long as possible

death

T I M E

apoB, apolipoprotein B; LDL-C, low-density lipoprotein cholesterol

…estimated real-world LDL-C reduction of only 23% to 35%

Today's Approach:

Transient LDL-C Reduction, Inadequate Efficacy

Lipid-lowering therapy

~40 mg/dL

21% Major CVD

Event Reduction1

reduction

over 5 years

Learnings from lipid lowering trials:*

5 years of consistent LDL-C lowering reduces major cardiovascular event risk by 21%

Efficacy is Compromised

by Frequent Discontinuation

PCSK9

mAb

siRNA

Dosing

Injection every

6 months

2 weeks

1-year Patient

~1 in 5

~1 in 2

Discontinuation

Rate2

Estimated

Real-world

- 35%

- 23%

LDL-C Reduction

at 1 year3

*In 28 trials evaluating efficacy and safety of statin therapy. 1. Cholesterol Treatment Trialists' (CTT) Collaboration. Lancet 2019. 2. Popadic et al. Journal of Clinical Lipidology 2024. 3. Rosenson et al. 2025 ACC. Poster #12209

LDL-C, low-density lipoprotein cholesterol; CVD, cardiovascular disease; PCSK9, proprotein convertase subtilisin/kexin type 9; siRNA, small interfering RNA; mAb, monoclonal antibody

Disclaimer

Verve Therapeutics Inc. published this content on April 14, 2025, and is solely responsible for the information contained herein. Distributed via , unedited and unaltered, on April 14, 2025 at 14:13 UTC.